Monday, 21 Sep 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Finance
  • Clinical trial results
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US
CompanyDeals

Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal

July 7, 2026
Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation
CompanyDeals

Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation

July 7, 2026
Policy / Regulatory

Guangdong Launches “Spring Rain Action” to Accelerate Medical Device Innovation Transformation with 900+ Clinical Achievements Target

July 7, 2026
CompanyDeals

Astex Pharmaceuticals, Genentech Forge $515M Breast Cancer Small Molecule Drug Collaboration

July 7, 2026
Others

Novartis to Acquire Myricx Bio for $1.1 Billion to Strengthen ADC Pipeline with Novel N-Myristoyltransferase Inhibitor Payload Technology

July 6, 2026
Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases
CompanyDeals

Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases

July 6, 2026
iRegene Therapeutics Secures RMB 260 Million Series C+ Financing to Advance iPSC-Derived Parkinson's Disease Therapy with FDA Fast Track and RMAT Designations
CompanyDeals

iRegene Therapeutics Secures RMB 260 Million Series C+ Financing to Advance iPSC-Derived Parkinson’s Disease Therapy with FDA Fast Track and RMAT Designations

July 6, 2026
CompanyDrug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

July 6, 2026
CompanyDrug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

July 6, 2026
Others

China’s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways

July 6, 2026
CompanyDrug

Changchun High & New Tech Secures NMPA Clinical Approval for GenSci164 PTH1R Agonist in Hypoparathyroidism Treatment

July 6, 2026
Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management
CompanyDeals

Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management

July 6, 2026
1 2 … 17 18 19 20 21 22
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up